Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amaya, H., Tanigawa, N., Lu, C., Matsumura, M., Shimomatsuya, T., Horiuchi, T. & Muroaka, R. (1997). Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 119: 227–235.
Ambiru, S., Miyazaki, M., Ito, H., Nakagawa, K., Shimizu, H., Nukui, Y., Nozawa, S., Okuno, A., Yoshitomi, H. & Nakajima, N. (1997). A prospective study of prognostic value of type IV collagenase in colorectal cancer tissue. Dig Dis Sci 42: 1660–1665.
Anderson, S. N., Lovig, T., Breivik, J., Lund, E., Guadernack, G., Meling, G. I. & Rognum, T. O. (1996). K-ras mutations and prognosis in large-bowel carcinomas. Scand J Gastroenterol 32: 62–69.
Apolinario, R. M., van der Valk, P., de Jong, J. S., Deveille, W., Van Arkotte, J., Dingemans, A-MC, Van Mourik, J. C., Postmus, P. E., Pinedo, H. M. & Giaccone, G. (1997). Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J Clin Oncol 15: 2456–2466.
Arribas, R., Capellà , G., Tórtola, S., Masramon, L., Grizzle, W. E., Perucho, M. & Peinado, M. A. (1997). Assessment of genomic damage in colorectal cancer by DNA fingerprinting: prognostic applications. J Clin Oncol 15: 3230–3240.
Astler, V. B. & Coller, F. A. (1954). The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 192: 846–850.
Augenlicht, L. H., Wadler, S., Corner, G., Richards, C., Ryan, L., Multani, A. S., Pathak, S., Benson, A., Haller, D. & Heerdt, B. G. (1997). Low-level c-myc amplifications in human colonic carcinoma cell lines and tumours: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 1769–1775.
Baas, I. O., Mulder, J. R., Offerhaus, G. J. A., Vogelstein, B. & Hamilton, S. R. (1994). An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 172: 5–12.
Baretton, G. B., Vogt, M., Muller, C., Diebold, J., Schneiderbanger, K., Schmidt, M. & Lohrs, U. (1996a). Prognostic significance of p53 expression, chromosome 17 copy number, and DNA ploidy in non-metastasized colorectal carcinomas (stages IB and II). Scand J Gastroenterol 31: 481–489.
Baretton, G. B., Diebold, J., Christoforis, G., Vogt, M., Müller, C., Dopfer, K., Schneiderbanger, K., Schmidt, M. & Löhrs, U. (1996b). Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance. Cancer 77: 255–264.
Bartik, Z., Nordenskiöld, B. O. & Sun, Z-F (1997). p53 overexpression as a prognostic factor in patients with Dukes’ B colorectal adenocarcinoma. Int J Oncol 11: 1019–1023.
Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F. & Quirke, P. (1993). Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 104: 57–64.
Belluco, C., Guillem, J. G., Kemeny, N., Huang, Y., Klimstra, D., Berger, M. F. & Cohen, A. M. (1996). p53 Nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 14: 2696–2701.
Benhattar, J., Losi, L., Chaubert, P., Givel, J-C & Costa, J. (1993). Prognostic significance of K-ras mutations in colorectal carcinoma. Gastroenterology 104: 1044–1048.
Bennett, M. A., Kay, E. W., Mulcahy, H., O’Flaherty, L., O’Donoghue, D. P., Leader, M. & Croke, D. T. (1995). ras and p53 in the prediction of survival in Dukes’ stage B colorectal carcinoma. J Clin Pathol 48: M310–M315.
Bhatavdekar, J. M., Patel, D. D., Ghosh, N., Chikhlikar, P. R., Trivedi, T. I., Suthar, T. P., Doctor, S. S., Shah, N. G. & Balar, D. B. (1997). Coexpression of Bcl-2, c-Myc, and p53 oncoproteins as prognostic discriminants in patients with colorectal carcinoma. Dis Colon Rectum 40: 785–790.
Bosari, S. & Viale, G. (1995). The clinical significance of p53 aberrations in human tumors. Virchows Arch A Pathol Anat Histopathol 427: 229–241.
Bosari, S., Viale, G., Bossi, P., Maggioni, M., Coggi, G., Murray, J. J. & Lee, A. K. C. (1994). Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. J Natl Cancer Inst 86: 681–687.
Bosari, S., Moneghini, L., Graziani, D., Lee, A. K. C., Murray, J. J., Coggi, G. & Viale, G. (1995). Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Human Pathol 26: 534–540.
Brett, M. C., Pickard, M., Green, B., Howel-Evans, A., Smith, D. & Kinsella, A. (1996). p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer. Eur J Sur Oncol 22: 182–185.
Chambers, A. F. & Matrisian, L. M. (1997). Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89: 1260–1270.
Cohen, A. M., Tremiterra, S., Candela, F., Thaler, H. T. & Sigurdson, E. R. (1991). Prognosis of node-positive colon cancer. Cancer 67: 1859–1861.
Costa, A., Doci, R., Machen, C., Bignami, P., Faranda, A., Gennari, L. & Silvestrini, R. (1997). Cell proliferation-related markers in colorectal liver metastases: correlation with patients prognosis. J Clin Oncol 15: 2008–2014.
Cox, L. S. & Lane, D. P. (1995). Tumor suppressors, kinases and clamps – how p53 regulates the cell-cycle in response to DNA-damage. Bioessays 17: 510–508.
Dix, B. R., Robbins, P., Soong, R., Jenner, D., House, A. K. & Lacopetta, B. J. (1994). The common molecular genetic alterations in Dukes’ B and C colorectal carcinomas are not short-term prognostic indicators of survival. Int J Cancer 59: 747–751.
Dorudi, S., Hanby, A. M., Poulsom, R., Northover, J. & Hart, I. R. (1995). Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 71: 614–616.
Elnatan, J., Goh, H-S & Smith, D. R. (1996). C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 32A: 491–497.
Fearon, E. R. & Vogelstein, B. A. (1990). The genetic model for colorectal tumorigenesis. Cell 61: 759–767.
Findlay, M. P. N., Cunningham, D., Morgan, G., Clinton, S., Hardcastle, A. & Aherne, G. W. (1997). Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy. Br J Cancer 75: 903–909.
Ganesh, S., Sier, C. F. M., Heerding, M. M., Vankrieken, JHJM, Griffioen, G., Welvaart, K., van de Velde, C. J., Verheijen, J. H. & Lamers, C. B., Verspaget, H. W. (1996). Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes’ stage B and C colorectal cancer. Br J Cancer 75: 1793–1801.
Goh, H-S, Yao, J. & Smith, D. R. (1995). p53 Point mutation and survival in colorectal cancer patients. Cancer Res 55: 5217–5221.
Griffiths, L. & Stratford, I. J. (1997). Platelet-derived endothelial cell growth factor thymidine phosphorylase in tumour growth and response to therapy. Br J Cancer 76: 689–693.
Hall, P. A. & Lane, D. P. (1994). p53 in tumour pathology: can we trust immunohistochemistry? – Revisited!. J Pathol 172: 1–4.
Hermanek, P., Wiebelt, H., Staimner, D. & Riedl, S. (1995). Prognostic factors of rectum carcinoma – experience of the German multicentre study SGCRC. German Study Group Colo-Rectal Carcinoma. Tumori 81: 60–64.
Hoffmann, D., Moore, J. & Roder, D. (1997). Trends in survival from colonic cancer: The impact of subspecialization. Aus N Z J Surgery 67: 842–845.
Ishimuru, G., Ookawa, K., Yamaguchi, N., Sakamoto, M., Hirohashi, S., Muto, T. & Yokota, J. (1994). Allelic losses associated with the metastatic potential of colorectal carcinoma. Int J Oncol 5: 267–273.
Jackman, A. L., Kelland, L. R., Kimbell, R., Brown, M., Gibson, W., Aherne, G. W., Hardcastle, A. & Boyle, F. T. (1995). Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (tomudex) in one mouse and three human cell lines. Br J Cancer 71: 914–924.
Jen, J., Kim, H. G., Piantadosi, S., Liu, Z. F., Lecitt, R. C., Sistonen, P., Kinzler, K. W., Vogelstein, B. & Hamilton, S. R. (1994). Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 331: 213–221.
Johnston, P. G., Drake, J. C., Trepel, J. & Allegra, C. J. (1992). Immunological quantitation of thymidylate synthase using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive and -resistant human cancer cell lines. Cancer Res 52: 4306–4312.
Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A. & Allegra, C. J. (1994). The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 12: 2640–2647.
Johnston, P. G., Lenz, H-J, Leichman, C. G., Danenberg, K. D., Allegra, C. J., Danenberg, P. V. & Leichman, L. (1995). Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumours. Cancer Res 55: 1407–1412.
Kang, S. M., Maeda, K., Chung, Y. S., Onodda, N., Ogawa, Y., Takatsuka, S., Ogawa, M., Sawada, T., Nakata, B., Nishiguchi, Y., Ikehara, T., Okuno, M. & Sowa, M. (1997). Vascular endothelial growth factor expression correlates with hematogenous metastasis and prognosis in colorectal carcinoma. Oncol Rep 4: 381–384.
Kapitanovic, S., Radosevic, S., Kapitanovic, M., Ajndelinovic, S., Ferencic, Z., Tavassoli, M., Primorac, D., Sonicki, Z., Spaventi, S., Pavelic, K. & Spaventi, R. (1997). The expression of p185HER-2/neu correlates with the stage of disease and survival in colorectal cancer. Gastroenterology 112: 1103–1113.
Kay, E. W., Mulcahy, H., Walsh, C. B., Leader, M. & O’Donoghue, D. (1994). Cytoplasmic c-erb B2 protein expression correlates with survival in Dukes’ B colorectal carcinoma. Histopathology 25: 455–461.
Khine, K., Goh, H-S & Smith, D. R. (1995). Prognostic significance of chromosome 5q and 17p allelic deletion in colorectal adenocarcinomas. Int J Oncol 7: 631–635.
Kitadai, Y., Ellis, L. M., Tucker, S. L., Greene, G. F., Bucana, C. D., Cleary, K. R., Takahashi, Y., Tahara, E. & Fidler, I. J. (1996). Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am J Path 149: 1541–1551.
Kochhar, R., Halling, K. C., McDonnell, S., Schaid, D. J., French, A. J., O’Connell, M. J., Nagorney, D. M. & Thibodeau, S. N. (1997). Allelic imbalance and microsatellite instability in resected Dukes’ D colorectal cancer. Diagn Mol Pathol 6: 78–84.
Kornmann, M., Link, K. H., Lenz, H-J, Pillasch, J., Metzger, R., Butzer, U., Leder, G. H., Weindel, M., Safi, F., Danenberg, K. D., Beger, H. G. & Danenberg, P. V. (1997). Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett 118: 29–35.
Koshida, Y., Saegusa, M. & Okayasu, I. (1997). Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 75: 367–373.
Kressner, U. L. F., Lindmark, G., Gerdin, B., Pahlman, L. & Glimelius, B. (1996). Immunohistochemical p53 staining is of limited value in the staging and prognostic prediction of colorectal cancer. Anticancer Res 16: 951–958.
Kumar, V., Bustin, S. A. & Mckay, I. A. (1995). Transforming growth factor-alpha. Cell Biol Int 19: 373–388.
Lanza, G., Maestri, I., Dubini, A., Gafa, R., Santini, A., Ferretti, S. & Cavazzini, L. (1996). P53 expression in colorectal cancer. Relation to tumor type, DNA ploidy pattern, and short-term survival. Am J Clin Pathol 105: 604–612.
Lawrence, D. A. (1996). Transforming growth factor-beta – a general review. Eur Cytokine Network 7: 363–374.
Leahy, D. T., Salman, R., Mulcahy, H., Sheahan, K., O’Donoghue, D. P. & Parfrey, N. A. (1996). Prognostic significance of p53 abnormalities in colorectal carcinoma detected by PCR-SSCP and immunohistochemical analysis. J Pathol 180: 364–370.
Leichman, C. G., Lenz, H-J, Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M. & Danenberg, P. V. (1997). Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223–3229.
Linden, M. D., Nathanson, D. S. & Jacobson, G. (1996). Lack of prognostic significance of epidermal growth factor receptor expression in Dukes’ B colorectal carcinomas. Lab Invest 7461A: 343
Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F., Jessup, J. M. & Pagano, M. (1997). Increased proteasome-dependent degradation of the cyclin dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 3: 231–234.
Lowe, S. W., Ruley, H. E., Jacks, T. & Housman, D. E. (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74: 957–967.
Manne, U., Myers, R. B., Moron, C., Poczatek, R. B., Dillard, S., Weiss, H., Brown, D., Srivastava, S. & Grizzle, W. E. (1997). Prognostic significance of Bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer 74: 346–358.
Markowitz, S., Hines, J. D., Lutterbaugh, J., Myeroff, L., Mackay, W., Gordon, N., Rustum, Y., Luna, E. & Kleinerman, J. (1995). Mutant K-ras oncogenes in colon cancers do not predict patient’s chemotherapy response or survival. Clin Cancer Res 1: 441–445.
Mayer, A., Takimoto, M., Fritz, E., Schellander, G., Kofler, K. & Ludwig, H. (1993). The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 71: 2454–2460.
McArdle, C. S. & Hole, D. (1991). Impact of variability among surgeons on post-operative morbidity and mortality and ultimate survival. Br Med J 302: 1501–1505.
Miller, F., Heimann, T. M., Quish, A., Pyo, D. J., Szporn, A., Martinelli, G. & Fasy, T. M. (1992). Ras and c-myc protein expression in colorectal carcinoma. Dis Colon Rectum 35: 430–435.
Miyahara, M., Saito, T., Kaketani, K., Sato, K., Kuwahara, A., Shimoda, K. & Kobayashi, M. (1991). Clinical significance of ras p21 overexpression for patients with an advanced colorectal cancer. Dis Colon Rectum 34: 1097–1102.
Moertel, C. G., Fleming, T. R., MacDonald, J. S., Haller, D. G., Laurie, J. A., Tangen, C. M., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Veeder, M. H., Mailliard, J. A. & Graff, J. (1995). Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321–326.
Mulcahy, H. E., Duffy, M. J., Gibbons, D., McCarthy, P., Parfrey, N. A., O’Donoghue, D. P. & Sheahan, K. (1994). Urokinase type plasminogen activator and outcome in Dukes’ B colorectal cancer. Lancet 344: 583–584.
Mulder, J. W. R., Kruyt, P. M., Sewnath, M., Oosting, J., Seldenrijk, C. A., Weidema, W. F., Offerhaus, G. J. & Pals, S. T. (1994). Colorectal cancer prognosis and expression of exon-v6 containing CD44 proteins. Lancet 344: 1470–1472.
Murray, G. I., Duncan, M. E., O’Neil, P., Melvin, W. T. & Fothergill, J. E. (1996). Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Med 2: 461–462.
Nagai, M. A., Habr-Gama, A., Oshima, B. S. & Bretani, M. M. (1992). Association of genetic alterations of c-myc, c-fos, and c-Ha-ras proto-oncogenes in colorectal tumors. Frequency and clinical significance. Dis Colon Rectum 35: 444–451.
Nakamori, S., Kameyama, M., Imaoka, S., Furukawa, H., Ishikawa, O., Sasaki, Y., Kabuto, T., Iwanaga, T., Matsushita, Y. & Irimura, T. (1993). Increased expression of Sialyl Lewis antigen correlates with poor survival in patients with colorectal carcinoma: clinicopathological and immunohistochemical study. Cancer Res 53: 3632–3637.
Neoptolemos, J. P., Oates, G. D., Newbold, K. M., Robson, A. M., McConkey, C. & Powell, J. (1995). Cyclin/proliferation cell nuclear antigen immunohistochemistry does not improve the prognostic power of Dukes’ or Jass’ classifications for colorectal cancer. Br J Surg 82: 184–187.
Öfner, D., Riehemann, K., Maier, H., Riedmann, B., Nehoda, H., Tötsch, M., Böcker, W., Jasani, B. & Schmid, K. W. (1995). Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br J Cancer 72: 981–985.
Ogunbiyi, O. A., Goodfellow, P. J., Gagliardi, G., Swanson, P. E., Birnbaum, E. H., Fleshman, J. W., Kodner, I. J. & Moley, J. F. (1997). Prognostic value of chromosome 1 p allelic loss in colon cancer. Gastroenterology 113: 761–766.
Ogunbiyi, O. A., Goodfellow, P. J., Herfarth, K., Gagliardi, G., Swanson, P. E., Birnbaum, E. H., Read, T. E., Fleshman, J. W., Kodner, I. J. & Moley, J. F. (1998). Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 16: 427–433.
Paradiso, A., Rabinovich, M., Vallejo, C., Machiavelli, M., Romero, A., Perez, J., Lacava, J., Cuevas, M. A., Rodriquez, R., Leone, B., Sapia, M. G., Simone, G. & De Lena, M. (1996). p53 and PCNA expression in advanced colorectal cancer: response to chemotherapy and long-term prognosis. Int J Cancer 69: 437–441.
Parkin, D. M., Pisani, P. & Ferlay, J. (1993). Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594–606.
Poller, D. N., Baxter, K. J. & Shepherd, N. A. (1997). p53 and Rb1 protein expression: are they prognostically useful in colorectal cancer?. Br J Cancer 75: 87–93.
Pricolo, V. E., Finkelstein, S. D., WU, T-T, Keller, G., Bakker, A., Swalsky, P. A. & Bland, K. I. (1996). Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. Am J Surg 171: 41–46.
Reinbach, D. H., McGregor, J. R., Murray, G. D. & Odwyer, P. J. (1994). Effect of the surgeons speciality interest on the type of resection performed for colorectal-cancer. Dis Colon Rectum 37: 1020–1023.
Robson, H., Anderson, E., James, R. D. & Schofield, P. F. (1996). Transforming growth factor beta 1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients. Br J Cancer 74: 753–758.
Schneider, H. J., Sampson, S. A., Cunningham, D., Norman, A. R., Andreyev, H. J. N., Tilsed, J. V. T. & Clarke, P. A. (1997). Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br J Cancer 75: 427–431.
Schumacher, U., Higgs, D., Loizidou, M., Pickering, R., Leathem, A. & Taylor, I. (1994). Helix pomatia agglutinin binding is a useful prognostic indicator in colorectal carcinoma. Cancer 74: 3104–3107.
Shibata, D., Reale, M. A., Lavin, P., Silverman, M., Fearon, E. R., Steele, G., Jr, Jessup, J. M., Loda, M. & Summerhayes, I. C. (1996). The DCC protein and prognosis in colorectal cancer. N Engl J Med 335: 1727–1732.
Sinicrope, F. A., Hart, J., Michelassi, F. & Lee, J. J. (1995). Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res 1: 1103–1110.
Smith, D. R. & Goh, H-S (1996). Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Clin Cancer Res 2: 1049–1053.
Smith, D. R., Elnatan, J., Yao, J. & Goh, H-S (1996). Point mutation of the c-Ki-ras proto-oncogene and the p53 tumour suppressor gene in distal colonic adenocarcinomas. Int J Oncol 8: 1165–1169.
Soong, R., Grieu, F., Robbins, P., Dix, B., Chen, D., Parsons, R., House, A. & Lacopetta, B. (1997). P53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res 3: 1405–1411.
Span, M., Moerkerk, P. T., De Goeij, A. F. & Arends, J. W. (1996). A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer 69: 241–245.
Spitz, F. R., Giacco, G. G., Hess, K., Larry, L., Rich, T. A., Janjan, N., Cleary, K. R. & Skibber, J. M. (1997). P53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3: 1658–1690.
Sun, X. F., Wingren, S., Carstensen, J. M., Stål, O., Hatschek, T., Boeryd, B., Nordenskjöld, B. & Zhang, H. (1991). Ras p21 expression in relation to DNA ploidy, s-phase fraction and prognosis in colorectal adenocarcinoma. Eur J Cancer 27: 1646–1649.
Sun, X. F., Carsten, J. M., Zhang, H., Stal, O., Wingern, S., Hatschek, T. & Nordenskjold, B. (1992). Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373.
Sun, X. F., Carstensen, J. M., Stal, O., Zhang, H. & Nordenskjold, B. (1995). c-erb B2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcenoma. APMIS 103: 309–315.
Sun, X. F., Carstensen, J. M., Stal, O., Zhang, H. & Nordenskjold, B. (1996). Proliferating cell nuclear antigen (PCNA) in relation to ras, c-erbB-2, p53, clinico-pathological variables and prognosis in colorectal adenocarcinoma. Int J Cancer 69: 5–8.
Takahashi, Y., Tucher, S. L., Kitadai, Y., Koura, A. N., Bucana, C. D., Cleary, K. R. & Ellis, L. M. (1997). Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 132: 541–546.
Takebayashi, Y., Akiyama, S-I, Akiba, S., Yamada, K., Miyadera, K., Sumizawa, T., Yamada, Y., Murata, F. & Aikou, T. (1996). Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J Natl Cancer Inst 88: 1110–1117.
Wadler, S., Bajaj, R., Neuberg, D., Agarwal, V., Haynes, H. & Benson, A. L. B. (1997). Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: A study of the Eastern Cooperative Oncology Group (EST 2292). Cancer J Scientific Am 3: 284–289.
Witzig, T. E., Lopfinzi, C. L., Gonchoroff, N. J., Reiman, H. M., Cha, S. S., Wieand, H. S., Katzmann, J. A., Paulsen, J. K. & Moertel, C. G. (1991). DNA ploidy and cell kinetic measurements as predictors of reoccurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer 68: 879–888.
Wolmark, N., Wieand, H. S., Rockette, H. E., Fisher, B., Glass, A., Lawrence, W., Lerner, H., Cruz, A. B., Volk, H., Shibata, H., Evans, J. & Prager, D. (1983). The prognostic significance of tumour location and bowel obstruction in Dukes’ B and C colorectal cancer. Ann Surg 198: 743–750.
Wynford-Thomas, D. (1992). p53 in tumour pathology: can we trust immunohistochemistry?. J Pathol 166: 329–330.
Yamaguchi, A., Nakagawara, G., Kurosaka, Y., Nishimura, G., Yonemura, Y. & Miyazaki, I. (1993). P53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance. Br J Cancer 68: 399–402.
Yamaguchi, A., Urano, T., Goi, T., Saito, M., Takeuchi, K., Hirose, K., Nakagawara, G., Shiku, H. & Furukawa, K. (1996). Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients. J Clin Oncol 14: 1122–1127.
Younes, M., Fernandez, L. & Lechago, J. (1996). Transforming growth factor alpha (TGF-α) expression in biopsies of colorectal carcinoma is a significant prognostic indicator. Anticancer Res 16: 1999–2004.
Zeng, Z. S., Sarkis, A. S., Zhang, Z. F., Klimstra, D. S., Charytonowicz, E., Guillem, J. G., Cordon-Cardo, C. & Cohen, A. M. (1994). P53 nuclear overexpression – an independent predictor of survival in lymph node positive colorectal cancer patients. J Clin Oncol 12: 2043–2050.
Zeng, Z. S., Huang, Y., Cohen, A. M. & Guillem, J. G. (1996). Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J Clin Oncol 14: 3133–3140.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
McLeod, H., Murray, G. Tumour markers of prognosis in colorectal cancer. Br J Cancer 79, 191–203 (1999). https://doi.org/10.1038/sj.bjc.6690033
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690033
Keywords
This article is cited by
-
High expression of matrix metalloproteinases 16 is associated with the aggressive malignant behavior and poor survival outcome in colorectal carcinoma
Scientific Reports (2017)
-
MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance
Virchows Archiv (2016)
-
Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review
Clinical and Translational Oncology (2014)
-
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 10 (KLK10) in colorectal cancer
Tumor Biology (2012)
-
Dilated SMV in Colon Cancer—Is There any Significance
Journal of Gastrointestinal Cancer (2012)
